Filing Flows › Comparisons › BIAF vs ISPC
bioAffinity Technologies vs iSpecimen: BIAF and ISPC compared
bioAffinity Technologies is the larger company: $1.1M of revenue in its latest quarter (Q3 2026) against $152K for iSpecimen (Q2 2026). bioAffinity Technologies is growing faster (-26% against -79% a year earlier). bioAffinity Technologies is more profitable, with an operating margin of -328.0% against -897.1%.
Where the money goes: BIAF and ISPC
bioAffinity Technologies (BIAF) · Q3 2026
bioAffinity Technologies, Q3 2026: revenue $1.1M (-26% year over year), operating margin -328.0%, net loss $5.3M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
iSpecimen (ISPC) · Q2 2026
iSpecimen, Q2 2026: revenue $152K (-79% year over year), operating margin -897.1%, net loss $1.4M, operating cash flow −$690K. The chart follows the revenue to costs, profit and cash.
| bioAffinity Technologies (BIAF) | iSpecimen (ISPC) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $1.1M | $152K |
| Revenue growth, Y/Y | -26% | -79% |
| Operating margin | -328.0% | -897.1% |
| Net earnings | −$5.3M | −$1.4M |
| Net margin | -493.1% | -896.9% |
| Operating cash flow | −$3.9M | −$690K |
Where the revenue comes from
bioAffinity Technologies
- Health Care, Patient Service: $863K (81%)
- Histology Service Fees: $190K (18%)
- Medical Director Fees: $17K (2%)
iSpecimen
- Product: $125K (83%)
- Shipping and Handling: $27K (17%)
Questions
Which is bigger, bioAffinity Technologies or iSpecimen?
bioAffinity Technologies is the larger company: $1.1M of revenue in its latest quarter (Q3 2026) against $152K for iSpecimen (Q2 2026).
Is bioAffinity Technologies or iSpecimen growing faster?
bioAffinity Technologies is growing faster (-26% against -79% a year earlier).
Which is more profitable, bioAffinity Technologies or iSpecimen?
bioAffinity Technologies is more profitable, with an operating margin of -328.0% against -897.1%.
More: bioAffinity Technologies earnings · how bioAffinity Technologies makes money · iSpecimen earnings · how iSpecimen makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.